Page 1

Exact Sciences Announces First Quarter 2021 Results 05/04/2021 MADISON , Wis . , May 4 , 2021 / PRNewswire / -- Exact Sciences Corp. ( Nasdaq : EXAS ) today announced that the company generated revenue of $ 402.1 million for the first quarter ended March 31 , 2021 , compared to $ 347.8 million for the same period of 2020 . " The first quarter demonstrated Exact Sciences is well - positioned for growth today and into the future , " said Kevin Conroy , Chairman and CEO . " Our Cologuard® and Oncotype® tests help people in need of answers , including those who have been vulnerable during the pandemic . We plan to bring additional solutions to patients throughout the course of their diagnosis and treatment . " First Quarter 2021 Financial Results For the three - month period ended March 31 , 2021 , as compared to the same period of 2020 ( where applicable ) : ● EXACT SCIENCES ● ● Total revenue was $ 402.1 million , an increase of 16 percent Screening revenue was $ 240.3 million , an increase of 10 percent Precision Oncology revenue was $ 129.4 million , an increase of 1 percent COVID - 19 testing revenue was $ 32.3 million Gross margin including amortization of acquired intangible assets was 68 % , and non - GAAP gross margin excluding amortization of acquired intangible assets was 73 % Income tax benefit was $ 242.8 million due to a change in the deferred tax asset valuation allowance resulting from the Thrive combination Net loss was $ 31.2 million , or $ 0.18 per share , compared to a net loss of $ 134.6 million , or $ 0.91 per share EBITDA was $ ( 225.7 ) million and adjusted EBITDA was $ ( 23.5 ) million